# Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

> **NCT07446855** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 180 (estimated)

## Conditions studied

- Solid Tumours

## Interventions

- **DRUG:** AZD4956
- **DRUG:** Saruparib

## Key facts

- **NCT ID:** NCT07446855
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-17
- **Primary completion:** 2030-03-29
- **Final completion:** 2030-03-29
- **Target enrollment:** 180 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07446855

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07446855, "Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07446855. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*